Why CSL is still a buy | Money Management

Nevertheless, Australian equities manager Malcolm Whitten from Tyndall Asset Management and Marcus Bogdan from Blackmore Capital were optimistic on the business.
“We think CSL is fair value, it was a safe haven in COVID-19 and a potential vaccine supplier. But on the re-opening, it underperformed, and that underperformance created opportunities to re-enter the stock,” said Whitten, who managed the Nikko AM Australian Shares Income fund.
“While it was in lockdown, people were scared to go out and donate blood so the lack of blood availability constrained supply. But now the fading effects of the welfare payments in the US should mean supply increases; when there is high unemployment then blood donations increase.

Related Keywords

Australia , Australian , Marcus Bogdan , Malcolm Whitten , Pfizer , Astrazeneca , University Of Queensland , Tyndall Asset Management , Blackmore Capital , Shares Income , Csl , Tyndall , Ovid0 19 , Nikko Am , ஆஸ்திரேலியா , ஆஸ்திரேலிய , மார்கஸ் போக்டன் , ஃபைசர் , பல்கலைக்கழகம் ஆஃப் குயின்ஸ்லாந்து , டைண்டால் சொத்து மேலாண்மை , பிளாக்மோர் மூலதனம் , பங்குகள் வருமானம் , கிஸ்ல் ,